Serial changes in myocardial fluorodeoxyglucose uptake on routine oncologic PET during breast cancer chemotherapy: are they clinically relevant?

OBJECTIVE: Cancer therapy-related cardiac dysfunction is an important prognostic factor in patients with breast cancer undergoing chemotherapy. We evaluated serial changes in myocardial fluorodeoxyglucose (FDG) uptake on routine oncologic PET and assessed whether these changes differed according to chemotherapy regimen. METHODS: We retrospectively analyzed 535 FDG PET examinations obtained before and after chemotherapy in 108 patients with breast cancer. Mean FDG uptake was measured in the myocardium with the highest accumulation and in the descending aorta on the same cross-section, and their ratio was defined as the myocardial standard uptake ratio (M-SUR). Chemotherapy regimens were classified as anthracyclines, human epidermal growth factor receptor 2 (HER2) inhibitors, immune checkpoint inhibitors (ICI), and others. Pre- and post-treatment M-SUR values were compared using the paired t-test. RESULTS: A total of 309 paired examinations were analyzed: anthracyclines, 34 pairs (n = 17); HER2 inhibitors, 146 pairs (n = 40); ICI, 20 pairs (n = 9); and others, 109 pairs (n = 54). M-SUR significantly increased after anthracycline therapy (3.45 ± 2.44 to 5.37 ± 3.67, P = 0.046) and ICI therapy (3.78 ± 2.94 to 4.98 ± 4.27, P = 0.0328). No significant change was observed in the HER2 inhibitor or other regimen groups. CONCLUSION: Serial FDG PET demonstrated regimen-dependent increases in myocardial FDG uptake after anthracycline and ICI therapy. Routine oncologic PET may reflect chemotherapy-related myocardial metabolic alterations.

Authors

Institutions

Publication Details

Journal
Nuclear Medicine Communications
Published
2026-11-17
DOI
https://doi.org/10.1097/mnm.0000000000002220
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serial changes in myocardial fluorodeoxyglucose uptake on routine oncologic PET during breast cancer chemotherapy: are they clinically relevant?

Yui Maekawa, Yoko Satoh, Yukako Izoe, Hiroko Tsukada et al.
2 links
Nuclear Medicine Communications
Chemotherapy-induced cardiotoxicity and mitigation
article

Serial changes in myocardial fluorodeoxyglucose uptake on routine oncologic PET during breast cancer chemotherapy: are they clinically relevant?

Yui Maekawa, Yoko Satoh, Yukako Izoe, Hiroko Tsukada, Hideyuki Saya, Atsushi Yamamoto, Shuji Sakai, Satoki Watanabe, Michinobu Nagao, Sadako Akashi‐Tanaka, Ryotaro Ando
article en

Abstract

OBJECTIVE: Cancer therapy-related cardiac dysfunction is an important prognostic factor in patients with breast cancer undergoing chemotherapy. We evaluated serial changes in myocardial fluorodeoxyglucose (FDG) uptake on routine oncologic PET and assessed whether these changes differed according to chemotherapy regimen. METHODS: We retrospectively analyzed 535 FDG PET examinations obtained before and after chemotherapy in 108 patients with breast cancer. Mean FDG uptake was measured in the myocardium with the highest accumulation and in the descending aorta on the same cross-section, and their ratio was defined as the myocardial standard uptake ratio (M-SUR). Chemotherapy regimens were classified as anthracyclines, human epidermal growth factor receptor 2 (HER2) inhibitors, immune checkpoint inhibitors (ICI), and others. Pre- and post-treatment M-SUR values were compared using the paired t-test. RESULTS: A total of 309 paired examinations were analyzed: anthracyclines, 34 pairs (n = 17); HER2 inhibitors, 146 pairs (n = 40); ICI, 20 pairs (n = 9); and others, 109 pairs (n = 54). M-SUR significantly increased after anthracycline therapy (3.45 ± 2.44 to 5.37 ± 3.67, P = 0.046) and ICI therapy (3.78 ± 2.94 to 4.98 ± 4.27, P = 0.0328). No significant change was observed in the HER2 inhibitor or other regimen groups. CONCLUSION: Serial FDG PET demonstrated regimen-dependent increases in myocardial FDG uptake after anthracycline and ICI therapy. Routine oncologic PET may reflect chemotherapy-related myocardial metabolic alterations.

Nuclear Medicine Communications
Fujita Health University (JP), Fujita Health University Hospital (JP), Tokyo Women's Medical University (JP)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon